Vigil Neuroscience, Inc. (VIGL)

Market Cap	383.99M
Revenue (ttm)	n/a
Net Income	-92.17M
EPS	-2.10
Shares Out	47.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,506,711
Open	8.05
Previous Close	8.05
Day's Range	8.04 - 8.10
52-Week Range	1.31 - 8.10
Beta	3.34
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 5, 2025

About VIGL

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain in the United States. The company’s lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurode...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 7, 2022
• Employees: 69
• Stock Exchange: NASDAQ
• Ticker Symbol: VIGL
• Website: https://www.vigilneuro.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error